Immune globulin usage trends in commercially insured and Medicare populations, 2009-2019.
administration
blood management
intravenous immunoglobulin
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
09
12
2022
received:
03
10
2022
accepted:
09
12
2022
pubmed:
23
2
2023
medline:
23
3
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Longitudinal patterns of immune globulins (IG) use have not been described in large populations. Understanding IG usage is important given potential supply limitations impacting individuals for whom IG is the sole life-saving/health-preserving therapy. The study describes US IG utilization patterns from 2009 to 2019. Using IBM MarketScan commercial and Medicare claims data, we examined four metrics overall and by condition-specific categories during 2009-2019: (1) IG administrations per 100,000 person-years, (2) IG recipients per 100,000 enrollees, (3) average annual administrations per recipient, and (4) average annual dose per recipient. In the commercial and Medicare populations respectively: IG administrations per 100,000 person-years increased by 120% (213-470) and 144% (692-1693); IG recipients per 100,000 enrollees grew by 71% (24-42) and 102% (89-179); average annual administrations per recipient rose by 28% (8-10) and 19% (8-9); and average annual dose (grams) per recipient increased by 29% (384-497) and 34% (317-426). IG administrations associated with immunodeficiency (per 100,000 person-years) increased by 154% (from 127 to 321) and 176% (from 365 to 1007). Autoimmune and neurologic conditions were associated with higher annual average administrations and dose than other conditions. IG use increased, coinciding with a growth in the IG recipient population in the United States. Several conditions contributed to the trend, with the largest increase observed among immunodeficient individuals. Future investigations should assess changes in the demand for IVIG by disease state or indication and consider treatment effectiveness.
Sections du résumé
BACKGROUND
Longitudinal patterns of immune globulins (IG) use have not been described in large populations. Understanding IG usage is important given potential supply limitations impacting individuals for whom IG is the sole life-saving/health-preserving therapy. The study describes US IG utilization patterns from 2009 to 2019.
STUDY DESIGN AND METHODS
Using IBM MarketScan commercial and Medicare claims data, we examined four metrics overall and by condition-specific categories during 2009-2019: (1) IG administrations per 100,000 person-years, (2) IG recipients per 100,000 enrollees, (3) average annual administrations per recipient, and (4) average annual dose per recipient.
RESULTS
In the commercial and Medicare populations respectively: IG administrations per 100,000 person-years increased by 120% (213-470) and 144% (692-1693); IG recipients per 100,000 enrollees grew by 71% (24-42) and 102% (89-179); average annual administrations per recipient rose by 28% (8-10) and 19% (8-9); and average annual dose (grams) per recipient increased by 29% (384-497) and 34% (317-426). IG administrations associated with immunodeficiency (per 100,000 person-years) increased by 154% (from 127 to 321) and 176% (from 365 to 1007). Autoimmune and neurologic conditions were associated with higher annual average administrations and dose than other conditions.
DISCUSSION
IG use increased, coinciding with a growth in the IG recipient population in the United States. Several conditions contributed to the trend, with the largest increase observed among immunodeficient individuals. Future investigations should assess changes in the demand for IVIG by disease state or indication and consider treatment effectiveness.
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-530Informations de copyright
© 2023 AABB.
Références
Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46.
Appleby J. Niche drugs become victims of their own success as off-label use leads to shortages 2019. Available from: https://www.latimes.com/science/story/2019-09-24/off-label-use-drug-shortages.
Boyle JG. Immunoglobulin product availability issues: the sky is not falling but the world needs more plasma immune deficiency foundation 2019. Available from: https://primaryimmune.org/news/ig-availabilty-issues.
Loftus P. Drug shortage leaves patients without immune-disorder treatment. Wall Street Journal. 2019. Available from: https://www.wsj.com/articles/drug-shortage-leaves-patients-without-immune-disorder-treatment-11565343023.
Rosenkrantz H. A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing. The Washington Post. 2019.
FDA. Information about immune globulin (human) product shortage 2019. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-about-immune-globulin-human-product-shortage.
FDA. Immune globulin intravenous (IGIV) indications. Available from: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulin-intravenous-igiv-indications.
Shemer A, Kivity S, Shoenfeld Y. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study. Transfusion. 2018;58(2):430-8.
Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina EY. Changing trends in IVIG use in pediatric patients: a retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol. 2019;76:105868.
Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S. Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEaL patient registry. J Manag Care Spec Pharm. 2017;23(4):400-6.
Okubo Y, Handa A. Nationwide trend analysis of pediatric inpatients with immune thrombocytopenia in the United States. J Pediatr Hematol Oncol. 2018;40(3):e140-e4.
Murphy MSQ, Tinmouth A, Goldman M, Chasse M, Colas JA, Saidenberg E, et al. Trends in IVIG use at a tertiary care Canadian center and impact of provincial use mitigation strategies: 10-year retrospective study with interrupted time series analysis. Transfusion. 2019;59(6):1988-96.
Scott D, Dores G, Zhou C, Shoaibi A, Wong H-L, Chillarige Y, et al. Assessment of immunoglobulin utilization and shortage 2021. Available from: https://www.bestinitiative.org/wp-content/uploads/2020/10/IG_Utilization_Protocol_2020.pdf.
Quinn J, Orange JS, Modell V, Modell F. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…One at a time. Immunol Res. 2020;68(1):48-53.
Hsu LI, Chen JW, Lin DT, Hung YS, Hou SM. Clinical use of intravenous immunoglobulin in Taiwan: a 10-year population study. J Formos Med Assoc. 2021;120(10):1921-5.
Lowes A. Octagam withdrawn from market over unresolved blood clots. Embolisms Medspace. 2010. Available from: https://www.medscape.com/viewarticle/729411.
Anterasian C, Duong R, Gruenemeier P, Ernst C, Kitsen J, Geng B. Quality of life differences for primary immunodeficiency patients on home SCIG versus IVIG. J Clin Immunol. 2019;39(8):814-22.
Runken MC, Noone JM, Blanchette CM, Zacherle E, Howden R. Differences in patient demographics and healthcare costs of patients with PIDD receiving intravenous or subcutaneous immunoglobulin therapies in the United States. Am Health Drug Benefits. 2019;12(6):294-304.
Rocchio MA, Schurr JW, Hussey AP, Szumita PM. Intravenous immune globulin stewardship program at a tertiary Academic Medical Center. Ann Pharmacother. 2017;51(2):135-9.